Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

OctoPlus convenes EGM on 15 January 2013


Print article Print article
Copyright © Thomson Reuters 2012. All rights reserved.
2012-12-03 17:50:57 -

With reference to the joint press releases by OctoPlus N.V. ("OctoPlus" or the
"Company") (Euronext: OCTO) and Dr. Reddy's Laboratories Ltd. ("Dr.
Reddy's")
dated 22 October 2012 and 16 November 2012, OctoPlus today announces that it
calls an Extraordinary General Meeting of Shareholders pursuant to Article
2:108a of the Dutch Civil Code (Burgerlijk wetboek) and in connection with the
intended public offer by an indirect wholly owned subsidiary of Dr. Reddy's for
all the issued and outstanding shares in the capital of OctoPlus pursuant to
Article 18, paragraph 1 of the Dutch Public Takeover Decree (Besluit openbare
biedingen Wft) (the "Decree").

Extraordinary General Meeting of Shareholders to take place on 15 January 2013
in Leiden
An Extraordinary General Meeting of Shareholders of OctoPlus has been called to
be held on 15 January 2013, 
14.00 hours CET, at OctoPlus' headquarters in Leiden. The meeting documents are now available in the Corporate Information section of the website www.octoplus.nl. This press release does not constitute or form part of an offer for ordinary shares in OctoPlus. It is an announcement that an Extraordinary General Meeting of Shareholders of OctoPlus has been called. The information in this press release is not intended to be complete and for further information explicit reference is made to the offer memorandum, which is expected to be published mid December 2012, after approval of the Dutch Authority for the Financial Markets (Stichting Autoriteit Financiƫle Markten). In addition, a position statement of the Executive Board and Supervisory Board of OctoPlus shall be made available in accordance with Article 18, paragraph 2 and annex G of the Decree. For further information, please contact: For further information about OctoPlus, please contact Investor Relations: telephone number +31 (71) 524 1064, or send an e-mail to Investor Relations at IR@octoplus.nl. About OctoPlus OctoPlus is a specialty pharmaceutical company focused on the development and manufacture of improved injectable pharmaceuticals based on our proprietary drug delivery technologies that exhibit fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. OctoPlus also focuses on the development of long-acting, controlled release versions of known protein therapeutics, peptides and small molecules, including specialty generics. OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients. OctoPlus is listed on NYSE Euronext in Amsterdam under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl. This is a press release by OctoPlus pursuant to provisions of Article 5:25i of the Dutch Act on the Financial Supervision (Wet op het financieel toezicht) and Article 4, paragraph 3 of the Decree, in connection with the intended public offer by an indirect wholly owned subsidiary of Dr. Reddy's for all the issued and outstanding shares in the capital of OctoPlus. This document may contain certain forward-looking statements relating to the business, financial performance and results of the Company and the industry in which it operates. These statements are based on OctoPlus N.V.'s current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version. Click here for the press release in PDF: hugin.info/137076/R/1662098/538616.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: OctoPlus N.V. via Thomson Reuters ONE [HUG#1662098]


Press Information:




Contact Person:


Disclaimer: © 2014 Thomson Reuters. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Thomson Reuters's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com